These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2653712)

  • 1. Etoposide: an update.
    Fleming RA; Miller AA; Stewart CF
    Clin Pharm; 1989 Apr; 8(4):274-93. PubMed ID: 2653712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
    Karnaoukhova L; Moffat J; Martins H; Glickman B
    Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
    Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide].
    Desoize B; Maréchal F; Cattan A
    Ann Biol Clin (Paris); 1993; 51(2):125-8. PubMed ID: 8214810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment.
    de Jong RS; Mulder NH; Dijksterhuis D; de Vries EG
    Anticancer Res; 1995; 15(5B):2319-30. PubMed ID: 8572646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytotoxic mechanism and antineoplastic action of etoposide].
    Dołega A
    Postepy Hig Med Dosw; 1998; 52(1):67-87. PubMed ID: 9608232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
    Braybrooke JP; Levitt NC; Joel S; Davis T; Madhusudan S; Turley H; Wilner S; Harris AL; Talbot DC
    Clin Cancer Res; 2003 Oct; 9(13):4682-8. PubMed ID: 14581337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
    Suzuki K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins.
    McLeod HL; Evans WE
    Cancer Surv; 1993; 17():253-68. PubMed ID: 8137343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
    Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
    Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
    Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
    Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.